Document Detail


Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
MedLine Citation:
PMID:  25131979     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND: Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based anticoagulation regimen compared with a heparin-based anticoagulation regimen on ischaemic and bleeding outcomes.
METHODS: We searched Medline, the Cochrane Library, and relevant meeting abstracts (search done on April 9, 2014) for randomised trials that assessed bivalirudin versus heparin in patients planned for PCI. The primary efficacy endpoint was the incidence of major adverse cardiac events (MACE) up to 30 days. Secondary efficacy endpoints were death, myocardial infarction, ischaemia-driven revascularisation, and stent thrombosis. The primary safety endpoint was major bleeding up to 30 days. We calculated pooled risk ratios and 95% CIs using random-effects models.
FINDINGS: We included data from 16 trials involving 33 958 patients, of whom 2422 experienced MACE and 1406 had a major bleed. There was an increase in the risk of MACE with bivalirudin-based regimens compared with heparin-based regimens (risk ratio 1·09, 95% CI 1·01-1·17; p=0·0204), which was largely driven by increases in myocardial infarction (1·12, 1·03-1·23) and seemingly also by ischaemia-driven revascularisation (1·16, 0·997-1·34) with bivalirudin compared with heparin, with no effect on mortality (0·99, 0·82-1·18). Bivalirudin increased the risk of stent thrombosis (risk ratio 1·38, 95% CI 1·09-1·74; p=0·0074), which was primarily due to an increase in acute cases in ST-segment elevation myocardial infarction (4·27, 2·28-8·00; p<0·0001). Overall, bivalirudin-based regimens lowered the risk of major bleeding (risk ratio 0·62, 95% CI 0·49-0·78; p<0·0001), but the magnitude of this effect varied greatly (p<0·0001) depending on whether glycoprotein IIb/IIIa inhibitors were used predominantly in the heparin arm only (0·53, 0·47-0·61; p<0·0001), provisionally in both arms (0·78, 0·51-1·19; p=0·25), or planned in both arms (1·07, 0·87-1·31; p=0·53).
INTERPRETATION: Compared with a heparin-based regimen, a bivalirudin-based regimen increases the risk of myocardial infarction and stent thrombosis, but decreases the risk of bleeding, with the magnitude of the reduction depending on concomitant glycoprotein IIb/IIIa inhibitor use. Physicians should weigh the trade-off between ischaemic and bleeding events when choosing between different anticoagulant regimens.
FUNDING: None.
Authors:
Matthew A Cavender; Marc S Sabatine
Related Documents :
3058369 - Nonobstructive symptomatic plaques of the carotid bifurcation: echotomographic-angiogra...
23498679 - Napkin-ring sign on coronary ct angiography for the prediction of acute coronary syndrome.
23466769 - Utilization of beta blockers post-myocardial infarction.
23046599 - Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with...
23273339 - Exploring the reduction in myocardial infarctions in the plato trial: which patients be...
20133339 - Case report: hip septic arthritis and abcess after diagnostic coronary angiography.
6113759 - Improved right ventricular function and reduced pulmonary vascular resistance during pr...
668069 - The effect of ischemia on thallium-201 clearance from the myocardium.
1313369 - Haematological prognostic indices after myocardial infarction: evidence from the diet a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Lancet     Volume:  384     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-08-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  599-606     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2014 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections
Comment In:
Lancet. 2014 Aug 16;384(9943):564-6   [PMID:  25131970 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patien...
Next Document:  LDL cholesterol: controversies and future therapeutic directions.